Rotmann, A; Vekony, N; Gassner, D et al.
Activation of classical protein kinase C reduces the expression of human cationic amino acid transporter 3 (hCAT-3) in the plasma membrane.Biochem J. Bd. 395. H. 1. 2006 S. 117-23
Wojnowski, L
ADHD drugs and cardiovascular riskN Engl J Med. Bd. 354. H. 21. 2006 S. 2296-8; author reply 2296-8
Niemi, M; Arnold, KA; Backman, JT et al.
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.Pharmacogenet Genomics. Bd. 16. H. 11. 2006 S. 801-8
Wojnowski, L; Kamdem, LK
Clinical implications of CYP3A polymorphisms.Expert Opin Drug Metab Toxicol. Bd. 2. H. 2. 2006 S. 171-82
Pommerening, K; Muscholl, M
Datenschutz und DatensicherheitB. Herbig, A. Büssing (Hrsg). Informations- und Kommunikationstechnologien im Krankenhaus. Stuttgart: Schattauer Verlag 2006
Kamdem, LK; Meineke, I; Gödtel-Armbrust, U et al.
Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1.Chem Res Toxicol. Bd. 19. H. 4. 2006 S. 577-86
Förstermann, U; Münzel, T
Endothelial nitric oxide synthase in vascular disease: from marvel to menace.Circulation. Bd. 113. H. 13. 2006 S. 1708-14
Geber, C; Mang, CF; Kilbinger, H
Facilitation and inhibition by capsaicin of cholinergic neurotransmission in the guinea-pig small intestine.Naunyn Schmiedebergs Arch Pharmacol. Bd. 372. H. 4. 2006 S. 277-83
Schirmer, M; Toliat, MR; Haberl, M et al.
Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.Pharmacogenet Genomics. Bd. 16. H. 1. 2006 S. 59-71
Lang, T; Haberl, M; Jung, D et al.
Genetic variability, haplotype structures, and ethnical diversity of hepatic transporters MDR3 (ABCB4) and BSEP (ABCB11).Drug Metab Dispos. Bd. 34. H. 9. 2006 S. 1582-1599